Case Details
- Citation: [2017] SGHC 74
- Title: Intas Pharmaceuticals Ltd v DealStreetAsia Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 10 April 2017
- Judges: George Wei J
- Coram: George Wei J
- Case Number: Originating Summons 734 of 2016 (Registrar’s Appeals Nos 362 and 378 of 2016)
- Proceedings Type: Pre-action interrogatories and pre-action discovery (disclosure of documents)
- Plaintiff/Applicant: Intas Pharmaceuticals Limited (“Intas”)
- Defendant/Respondent: DealStreetAsia Pte Ltd (“DealStreetAsia”)
- Legal Area: Civil Procedure — Disclosure of Documents — Discovery of Documents — Pre-action Disclosure — Norwich Pharmacal Orders
- Counsel for Plaintiff/Applicant: Ang Cheng Hock SC, Lim Jun Rui, Ivan and Ramesh Kumar s/o Ramasamy (Allen & Gledhill LLP)
- Counsel for Defendant/Respondent: Sim Bock Eng, Sngeeta Rai and Lim Si Wei, Samuel (WongPartnership LLP)
- Key Procedural History: Appeal to this decision in Civil Appeal No 89 of 2017 withdrawn on 25 May 2017
- Judgment Length: 16 pages, 9,098 words
- Statutes Referenced: First Schedule of the Supreme Court of Judicature Act; Prevention of Corruption Act
- Rules Referenced: Rules of Court (Cap 322, R 5, 2014 Rev Ed), including O 24 r 6(1) and (5), and O 26A r 1(1) and (5)
- Notable Authorities Cited: Norwich Pharmacal Co v Customs and Excise Commissioners [1974] AC 133
Summary
This High Court decision concerns an application for pre-action disclosure in the context of a dispute arising from an allegedly false business report published on a Singapore financial news website. Intas, a pharmaceutical manufacturer, sought pre-action interrogatories and pre-action discovery against DealStreetAsia after an article reported that a competitor, Sun Pharmaceuticals Industries Ltd (“SPI”), was in “early talks” to acquire Intas. Intas denied the report and demanded explanations and an apology, but DealStreetAsia refused to provide the information requested about its sources and the basis for its “due diligence”.
The court (George Wei J) allowed Intas’s appeal in part and dismissed DealStreetAsia’s appeal. Substantively, the court ordered DealStreetAsia to provide certain categories of documents supporting the “reliable sources” assertions in the published article and its editor’s note. However, the court declined to grant all of Intas’s requested pre-action interrogatories and did not accept that the identity of sources was sufficiently material at the pre-action stage to justify full disclosure. The decision therefore illustrates the careful balancing Singapore courts undertake between enabling a claimant to assess and pursue a potential cause of action and protecting confidentiality and the limits of pre-action discovery.
What Were the Facts of This Case?
Intas is an India incorporated company engaged in manufacturing, marketing and distributing pharmaceutical products. DealStreetAsia is a Singapore incorporated company operating a financial news website. The dispute arose from an article published on DealStreetAsia’s website on 21 December 2015. The article, written by DealStreetAsia correspondent Ms Bhawna Gupta (“Ms Gupta”), reported that SPI was in “early talks” to acquire Intas. The report was framed as information derived from “multiple sources familiar with the development” and “executive(s) who [are] directly aware of the development”.
Crucially, the day before publication, Ms Gupta had emailed Intas’s Chief Financial Officer, Mr Jayesh Shah (“Mr Shah”), seeking confirmation and additional details regarding the alleged intended acquisition. Mr Shah replied on the morning of 21 December 2015 denying the report, stating that it was “completely base less” and that Intas “fully deny it”. Intas later asserted that the report was false and lacked substantial proof.
DealStreetAsia maintained that it had sought reactions and comments from relevant parties and that it conducted “due diligence” before publishing. The article and a subsequent “Editor’s Note” stated that the story was based on information provided by “reliable sources” and published after following “all standard protocol”. The editor’s note also addressed the denial by Intas, stating that Intas’s comments/denial were included in the original version and that the publication was not intended to create confusion or harm Intas.
After publication, Intas’s Vice Chairman, Mr Binish Chudgar (“Mr Chudgar”), emailed Ms Gupta demanding an apology and describing the article as false and baseless. DealStreetAsia’s director and editor-in-chief, Mr Thomas Philip Joji (“Mr Joji”), responded that the company had carried out due diligence and published only after confirmations from reliable sources. Intas’s solicitors then wrote to DealStreetAsia requesting details of the due diligence and the identity of the sources relied upon. DealStreetAsia refused to furnish the requested information. Intas then instructed Singapore solicitors, who sent a further letter indicating an intention to commence proceedings for malicious falsehood and requesting information about the communications and the sources.
What Were the Key Legal Issues?
The central legal issues concerned the scope and availability of pre-action disclosure mechanisms under Singapore civil procedure. Intas sought leave to serve pre-action interrogatories and an order for pre-action discovery. The court had to decide whether the requested disclosure was permissible and, if so, what categories of documents should be disclosed and whether the identity of sources should be revealed at the pre-action stage.
Two related but distinct purposes were advanced by Intas. First, Intas argued that it needed disclosure to assess whether it had a viable cause of action for malicious falsehood against DealStreetAsia. Second, Intas argued that it needed disclosure to identify DealStreetAsia’s sources so that it could commence proceedings against those sources themselves. In substance, the second purpose resembled the remedy associated with Norwich Pharmacal orders, where a claimant seeks disclosure to identify a potential defendant.
Accordingly, the court had to consider how Singapore’s procedural rules on pre-action interrogatories and discovery interact with the principles governing Norwich Pharmacal-type relief, including materiality, necessity, and the protection of confidential information. The court also had to consider whether interrogatories were appropriate where the claimant’s case depended on communications that might include oral statements not captured in documentary discovery.
How Did the Court Analyse the Issues?
George Wei J began by setting out the factual matrix and the procedural posture: the application had been granted in part by the Assistant Registrar, with DealStreetAsia ordered to provide certain documents but permitted to redact information that might identify sources. The AR had declined to allow interrogatories and had reasoned that the identity of sources was not sufficiently material for the malicious falsehood claim against DealStreetAsia. On appeal, both parties challenged different aspects of the AR’s decision.
On the interrogatories issue, Intas’s position was that it required interrogatories because the sources might have communicated orally with DealStreetAsia, and documentary discovery would not reveal oral communications. The court’s analysis focused on whether interrogatories were necessary and proportionate for the pre-action stage. Pre-action interrogatories are not automatic; they are granted only where the procedural requirements are met and where the information sought is relevant to the claimant’s intended proceedings. The court was cautious about expanding pre-action tools in a way that would effectively compel disclosure of sensitive information without a sufficiently established basis.
On the discovery issue, the court examined the categories of documents ordered by the AR and the rationale for disclosure. The AR had required DealStreetAsia to disclose documents and correspondence evidencing the statements in the article and editor’s note that the story was based on information provided by “reliable sources” and that “multiple sources” and “executives directly aware” had told DealStreetAsia about the alleged acquisition. The court treated these “reliable sources” assertions as central to DealStreetAsia’s defence narrative and therefore as relevant to Intas’s ability to assess whether the publication could support a claim for malicious falsehood.
In allowing Intas’s appeal in part, the court required DealStreetAsia to provide further documentary support for the specific statements made in the article and editor’s note. This approach reflects a principle that pre-action discovery should be targeted: it should enable the claimant to evaluate the merits of the intended claim without turning the process into a general fishing expedition. By focusing on documents evidencing the “reliable sources” claims, the court ensured that Intas could test whether DealStreetAsia’s publication was grounded in verifiable information and whether the elements of malicious falsehood—particularly malice—could potentially be supported.
As to the identity of sources, the court did not accept that disclosure of source identities was automatically material at the pre-action stage. While Intas argued that source identity and the content of communications were relevant to malice, the court considered the threshold for ordering disclosure of identities in a Norwich Pharmacal-like context. Norwich Pharmacal relief is exceptional because it compels disclosure from a non-party or intermediary who is not the wrongdoer, and it engages confidentiality and the risk of chilling legitimate journalistic or commercial information flows. The court therefore required a more disciplined showing of necessity and materiality before ordering disclosure that would identify sources.
In this case, the court’s reasoning indicates that the claimant’s need to assess a claim against the publisher could be satisfied, at least initially, by documentary discovery relating to the publisher’s stated basis for publication, rather than by immediate disclosure of source identities. The court’s decision to permit redaction of identifying information (subject to the ordered categories) reflects this balancing exercise. In other words, the court treated documentary evidence of the “reliable sources” process as sufficiently connected to the malicious falsehood inquiry, while treating source identity as a further step requiring stronger justification.
What Was the Outcome?
The court allowed Intas’s appeal in part and dismissed DealStreetAsia’s appeal. Practically, DealStreetAsia was ordered to provide pre-action discovery of documents and correspondence evidencing the specific “reliable sources” statements made in the article and the editor’s note—particularly those describing multiple sources familiar with the development, executives directly aware of the development, and the involvement of advisory firms and reactions sought.
At the same time, the court upheld the refusal of pre-action interrogatories and did not require full disclosure of the identity of sources at the pre-action stage. The effect of the decision is that Intas could obtain targeted documentary material to evaluate its malicious falsehood claim against DealStreetAsia, but it could not compel immediate identification of the sources through interrogatories or broader disclosure.
Why Does This Case Matter?
This case is significant for practitioners because it clarifies how Singapore courts approach pre-action disclosure in disputes involving publication and alleged malicious falsehood. It demonstrates that courts will not treat pre-action discovery as a mechanism for comprehensive discovery of all information that might be relevant; instead, they will require a structured and targeted connection between the documents sought and the elements of the intended cause of action.
From a Norwich Pharmacal perspective, the decision underscores that orders compelling disclosure of source identities are exceptional and will be granted only where the claimant shows that such disclosure is sufficiently material and necessary. The court’s willingness to order documentary discovery relating to the publisher’s stated reliance on “reliable sources” shows a middle path: claimants may be able to assess malice and viability without immediately breaching confidentiality by identifying sources.
For law students and litigators, the case is also useful as an example of how procedural rules on pre-action interrogatories and pre-action discovery are applied in practice. It illustrates the importance of framing the disclosure request around specific statements and categories of documents, rather than seeking broad disclosure of communications and identities. Practitioners should therefore expect that courts will scrutinise whether the requested information is genuinely necessary to evaluate the claim and whether less intrusive disclosure would suffice.
Legislation Referenced
- First Schedule of the Supreme Court of Judicature Act
- Prevention of Corruption Act
- Rules of Court (Cap 322, R 5, 2014 Rev Ed): O 24 r 6(1) and O 24 r 6(5); O 26A r 1(1) and O 26A r 1(5)
Cases Cited
- Norwich Pharmacal Co v Customs and Excise Commissioners [1974] AC 133
- [2017] SGHC 74 (the decision itself)
Source Documents
This article analyses [2017] SGHC 74 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.